Similar Search Results

Hospital Length of Stay for Schizophrenia: Is Primary Payer an Influencing Factor?

Sclar, David A.; Robison, Linda M.; Skaer, Tracy L.; … - In: Disease Management and Health Outcomes 5 (1999) 6, pp. 339-347

Objective: The purpose of this study was 3-fold: (i) to determine the distribution of US patients diagnosed with schizophrenia and requiring a hospitalisation in the calendar year 1988 or 1992, by primary payer type (Medicare; Medicaid; or private insurance); (ii) to discern the mean inpatient...

Persistent link: https://www.econbiz.de/10005590212

Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and C...

Blankart, Carl Rudolf.; Stargardt, Tom; Schreyogg, … - In: PharmacoEconomics 29 (2011) 1, pp. 63-82

costly orphan drugs because access depends primarily on co-payments, reimbursement policies and prices. The objective of this …

Persistent link: https://www.econbiz.de/10010614375

A Prospective View on European Pharmaceutical Research and Development: Policy Options to Reduce Fragmentation and Increase Competitiveness

Kanavos, Panos - In: PharmacoEconomics 13 (1998) 2, pp. 181-190

This article analyses 3 areas of policy that could reduce the fragmentation and improve the competitiveness of the European pharmaceutical sector. It argues that a potential solution to the issue of fragmentation of pharmaceutical research, development and innovation may be the development of...

Persistent link: https://www.econbiz.de/10005404808

Reform of Prescription Drug Reimbursement and Pricing in the German Social Health Insurance Market: A Comparison of Three Scenarios

Gress, Stefan; Niebuhr, Dea; May, Uwe; Wasem, Jurgen - In: PharmacoEconomics 25 (2007) 6, pp. 443-454

: regulation of reimbursement and pricing. We find that centralised regulation of reimbursement and pricing prevails in the 15 …, market approval is nearly always equivalent to reimbursement. Second, manufacturers are free to determine prices but internal … of prescriptions, three reform scenarios are feasible. The first scenario maintains centralised reimbursement and …

Persistent link: https://www.econbiz.de/10005404890

Physician-Patient e-Visit Programs: Implementation and Appropriateness

Whitten, Pamela; Buis, Lorraine; Love, Brad - In: Disease Management and Health Outcomes 15 (2007) 4, pp. 207-214

communication by patients, lack of reimbursement schemes, legal and regulatory issues, and concerns over security, privacy, and …

Persistent link: https://www.econbiz.de/10005590187

Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?

Puig-Junoy, Jaume - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 441-451

Background:Background: In many countries with generic reference pricing, generic producers and distributors compete by means of undisclosed discounts offered to pharmacies in order to reduce acquisition costs and to induce them to dispense their generic to patients in preference over others....

Persistent link: https://www.econbiz.de/10010585885

Guidelines for the Implementation of Patient-Controlled Analgesia

Campbell, Lynne; Plummer, John - In: Disease Management and Health Outcomes 4 (1998) 1, pp. 27-39

Intravenous patient-controlled analgesia (PCA) can provide improved postoperative pain control compared with traditional methods, while maintaining safety. However, poorly managed PCA cannot be expected to provide good analgesia and may increase the risk of adverse events. Effective use of PCA...

Persistent link: https://www.econbiz.de/10005243034

Screening, Diagnostic and Outcome Tools for Asthma

Wever, Anthony M.J.; Wever-Hess, Jopie; Britton, Mark G. - In: Disease Management and Health Outcomes 3 (1998) 5, pp. 229-238

Asthma is a chronic inflammatory disorder of the airways, affecting about 10% of children and 5 to 7% of the adult population. Improved asthma control will not only benefit the patient but will also result in reduced financial expenditure in asthma healthcare. This article summarises the tools...

Persistent link: https://www.econbiz.de/10005243039

Guidelines for the Prevention of Coronary Heart Disease: Relating Local Needs to Local Initiatives

Faergeman, Ole - In: Disease Management and Health Outcomes 4 (1998) 4, pp. 217-224

Coronary heart disease (CHD) emerged in North America and Europe as a leading cause of disease and death in the mid 20th century, and is now rapidly increasing in developing nations. By the mid 1980s, American and European academic institutions had issued several sets of guidelines indicating...

Persistent link: https://www.econbiz.de/10005243042

A Reappraisal of Economic Evaluation of Pharmaceuticals: Science or Marketing?

Drummond, Michael F. - In: PharmacoEconomics 14 (1998) 1, pp. 1-9

In pharmacoeconomic research sponsored by companies, there is an obvious tension between the desire to undertake studies to show a marketing advantage and the desire to adhere to good scientific principles. This tension was explored in an early issue of PharmacoEconomics and is now revisited 5...

Persistent link: https://www.econbiz.de/10005243219